JNJ's Growth Comparisons in III. Quarter 2026
Johnson And Johnson's Revenue slowed to the 5.86% year on year, improvement in the third quarter 2026 to 25.40 billions, underperforming the 14.14% rise in the Major Pharmaceutical Preparations industry and 10.2% Revenue improvement in the Healthcare sector. Comparing the third quarter, sales Johnson And Johnson was trailing overall market not just Major Pharmaceutical Preparations industry.
Comparing the company's Revenue to the second quarter results, sales were higher by 0.35% . On the yearly basis, average annual sales growth for Johnson And Johnson is 2.67%, while S & P 500's including only Businesses with the third quarter 2026 earnings, average annual sales growth is 13.63% over the past five years.
| Segment Name |
Y / Y |
Sequential |
| U S |
|
8.33 % |
- |
| International |
|
11.93 % |
- |
| Innovative Medicine |
|
11.19 % |
- |
| Innovative Medicine U S |
|
9.63 % |
- |
| Innovative Medicine International |
|
13.39 % |
- |
| Innovative Medicine Oncology |
|
22.81 % |
- |
| Innovative Medicine Oncology U S |
|
19.98 % |
- |
| Innovative Medicine Oncology International |
|
26.05 % |
- |
| Innovative Medicine Oncology DARZALEX |
|
22.46 % |
- |
| Innovative Medicine Oncology DARZALEX U S |
|
20.72 % |
- |
| Innovative Medicine Oncology DARZALEX International |
|
24.63 % |
- |
| Innovative Medicine Oncology CARVYKTI |
|
61.79 % |
- |
| Innovative Medicine Oncology CARVYKTI U S |
|
36.16 % |
- |
| Innovative Medicine Oncology CARVYKTI International |
|
221.57 % |
- |
| Innovative Medicine Oncology Tecvayli |
|
33.77 % |
- |
| Innovative Medicine Oncology Tecvayli U S |
|
20.95 % |
- |
| Innovative Medicine Oncology Tecvayli International |
|
60.87 % |
- |
| Innovative Medicine Oncology TALVEY |
|
76.74 % |
- |
| Innovative Medicine Oncology TALVEY U S |
|
48.53 % |
- |
| Innovative Medicine Oncology TALVEY International |
|
183.33 % |
- |
| Innovative Medicine Oncology RYBREVANT LAZCLUZE |
|
82.27 % |
- |
| Innovative Medicine Oncology RYBREVANT LAZCLUZE U S |
|
54.87 % |
- |
| Innovative Medicine Oncology RYBREVANT LAZCLUZE International |
|
192.86 % |
- |
| Innovative Medicine Oncology ERLEADA |
|
23.09 % |
- |
| Innovative Medicine Oncology ERLEADA U S |
|
17.12 % |
- |
| Innovative Medicine Oncology ERLEADA International |
|
26.72 % |
- |
| Innovative Medicine Oncology IMBRUVICA |
|
-6.91 % |
- |
| Innovative Medicine Oncology IMBRUVICA U S |
|
-39.15 % |
- |
| Innovative Medicine Oncology IMBRUVICA International |
|
9.07 % |
- |
| Innovative Medicine Oncology Other Oncology |
|
-10.28 % |
- |
| Innovative Medicine Oncology Other Oncology U S |
|
57.41 % |
- |
| Innovative Medicine Oncology Other Oncology International |
|
-33.75 % |
- |
| Innovative Medicine Immunology |
|
-8.82 % |
- |
| Innovative Medicine Immunology U S |
|
-15.53 % |
- |
| Innovative Medicine Immunology International |
|
0.93 % |
- |
| Innovative Medicine Immunology Tremfya |
|
- |
- |
| Innovative Medicine Immunology Tremfya U S |
|
- |
- |
| Innovative Medicine Immunology Tremfya International |
|
- |
- |
| Innovative Medicine Immunology SIMPONI SIMPONI ARIA |
|
-1.82 % |
- |
| Innovative Medicine Immunology SIMPONI SIMPONI ARIA U S |
|
-7.88 % |
- |
| Innovative Medicine Immunology SIMPONI SIMPONI ARIA International |
|
3.28 % |
- |
| Innovative Medicine Immunology Remicade |
|
- |
- |
| Innovative Medicine Immunology Remicade U S |
|
- |
- |
| Innovative Medicine Immunology Remicade International |
|
- |
- |
| Innovative Medicine Immunology STELARA |
|
-59.63 % |
- |
| Innovative Medicine Immunology STELARA U S |
|
-77.57 % |
- |
| Innovative Medicine Immunology STELARA International |
|
-32.45 % |
- |
| Innovative Medicine Immunology OTHER IMMUNOLOGY |
|
4500 % |
- |
| Innovative Medicine Immunology OTHER IMMUNOLOGY U S |
|
3700 % |
- |
| Innovative Medicine Immunology OTHER IMMUNOLOGY International |
|
- |
- |
| Innovative Medicine Infectious Diseases |
|
10.85 % |
- |
| Innovative Medicine Infectious Diseases U S |
|
8.57 % |
- |
| Innovative Medicine Infectious Diseases International |
|
12.32 % |
- |
| Innovative Medicine Infectious Diseases EDURANT rilpivirine |
|
14.25 % |
- |
| Innovative Medicine Infectious Diseases EDURANT rilpivirine U S |
|
-12.5 % |
- |
| Innovative Medicine Infectious Diseases EDURANT rilpivirine International |
|
14.86 % |
- |
| Innovative Medicine Infectious Diseases PREZISTA PREZCOBIX REZOLSTA SYMTUZA |
|
9.93 % |
- |
| Innovative Medicine Infectious Diseases PREZISTA PREZCOBIX REZOLSTA SYMTUZA U S |
|
9.51 % |
- |
| Innovative Medicine Infectious Diseases PREZISTA PREZCOBIX REZOLSTA SYMTUZA International |
|
11.22 % |
- |
| Innovative Medicine Infectious Diseases OTHER INFECTIOUS DISEASES |
|
-9.76 % |
- |
| Innovative Medicine Infectious Diseases OTHER INFECTIOUS DISEASES U S |
|
-50 % |
- |
| Innovative Medicine Infectious Diseases OTHER INFECTIOUS DISEASES International |
|
-7.69 % |
- |
| Innovative Medicine Neuroscience |
|
32.06 % |
- |
| Innovative Medicine Neuroscience U S |
|
54.34 % |
- |
| Innovative Medicine Neuroscience International |
|
0.29 % |
- |
| Innovative Medicine Neuroscience SPRAVATO |
|
46.25 % |
- |
| Innovative Medicine Neuroscience SPRAVATO U S |
|
47.1 % |
- |
| Innovative Medicine Neuroscience SPRAVATO International |
|
41.86 % |
- |
| Innovative Medicine Neuroscience CAPLYTA |
|
- |
- |
| Innovative Medicine Neuroscience CAPLYTA U S |
|
- |
- |
| Innovative Medicine Neuroscience INVEGA SUSTENNA XEPLION INVEGA TRINZA TREVICTA |
|
14.95 % |
- |
| Innovative Medicine Neuroscience INVEGA SUSTENNA XEPLION INVEGA TRINZA TREVICTA U S |
|
21.28 % |
- |
| Innovative Medicine Neuroscience INVEGA SUSTENNA XEPLION INVEGA TRINZA TREVICTA International |
|
1.08 % |
- |
| Innovative Medicine Neuroscience CONCERTA Methylphenidate |
|
- |
- |
| Innovative Medicine Neuroscience CONCERTA Methylphenidate U S |
|
- |
- |
| Innovative Medicine Neuroscience CONCERTA Methylphenidate International |
|
- |
- |
| Innovative Medicine Neuroscience OTHER NEUROSCIENCE |
|
-5.42 % |
- |
| Innovative Medicine Neuroscience OTHER NEUROSCIENCE U S |
|
35.71 % |
- |
| Innovative Medicine Neuroscience OTHER NEUROSCIENCE International |
|
-9.68 % |
- |
| Innovative Medicine Pulmonary Hypertension |
|
10.73 % |
- |
| Innovative Medicine Pulmonary Hypertension U S |
|
11.69 % |
- |
| Innovative Medicine Pulmonary Hypertension International |
|
8.19 % |
- |
| Innovative Medicine Pulmonary Hypertension UPTRAVI |
|
7.1 % |
- |
| Innovative Medicine Pulmonary Hypertension UPTRAVI U S |
|
5.48 % |
- |
| Innovative Medicine Pulmonary Hypertension UPTRAVI International |
|
13.95 % |
- |
| Innovative Medicine Pulmonary Hypertension OPSUMIT OPSYNVI |
|
16.09 % |
- |
| Innovative Medicine Pulmonary Hypertension OPSUMIT OPSYNVI U S |
|
19.28 % |
- |
| Innovative Medicine Pulmonary Hypertension OPSUMIT OPSYNVI International |
|
8.18 % |
- |
| Innovative Medicine Pulmonary Hypertension Other |
|
-11.54 % |
- |
| Innovative Medicine Pulmonary Hypertension Other U S |
|
-20 % |
- |
| Innovative Medicine Pulmonary Hypertension Other International |
|
-8.11 % |
- |
| Innovative Medicine Cardiovascular Metabolism Other |
|
-13.52 % |
- |
| Innovative Medicine Cardiovascular Metabolism Other U S |
|
-14.15 % |
- |
| Innovative Medicine Cardiovascular Metabolism Other International |
|
-10.13 % |
- |
| Innovative Medicine Cardiovascular Metabolism Other Other |
|
-27.86 % |
- |
| Innovative Medicine Cardiovascular Metabolism Other Other U S |
|
-44.85 % |
- |
| Innovative Medicine Cardiovascular Metabolism Other Other International |
|
-10.13 % |
- |
| Innovative Medicine Cardiovascular Metabolism Other XARELTO |
|
-6.96 % |
- |
| Innovative Medicine Cardiovascular Metabolism Other XARELTO U S |
|
-6.96 % |
- |
| Innovative Medicine Total PH ID CVM Other |
|
2.08 % |
- |
| Innovative Medicine Total PH ID CVM Other U S |
|
-0.37 % |
- |
| Innovative Medicine Total PH ID CVM Other International |
|
7.24 % |
- |
| MEDTECH |
|
7.68 % |
- |
| MEDTECH U S |
|
5.84 % |
- |
| MEDTECH International |
|
9.72 % |
- |
| MEDTECH Cardiovascular |
|
13.03 % |
- |
| MEDTECH Cardiovascular U S |
|
10.94 % |
- |
| MEDTECH Cardiovascular International |
|
16.15 % |
- |
| MEDTECH ELECTROPHYSIOLOGY |
|
12.55 % |
- |
| MEDTECH ELECTROPHYSIOLOGY U S |
|
7.6 % |
- |
| MEDTECH ELECTROPHYSIOLOGY International |
|
18.03 % |
- |
| MEDTECH ABIOMED |
|
16.19 % |
- |
| MEDTECH ABIOMED U S |
|
14.75 % |
- |
| MEDTECH ABIOMED International |
|
23.46 % |
- |
| MEDTECH Shockwave |
|
18.22 % |
- |
| MEDTECH Shockwave U S |
|
17.48 % |
- |
| MEDTECH Shockwave International |
|
21.15 % |
- |
| MEDTECH Other Cardiovascular |
|
-8.74 % |
- |
| MEDTECH Other Cardiovascular U S |
|
0 % |
- |
| MEDTECH Other Cardiovascular International |
|
-13.89 % |
- |
| MEDTECH Orthopaedics |
|
6.34 % |
- |
| MEDTECH Orthopaedics U S |
|
3.68 % |
- |
| MEDTECH Orthopaedics International |
|
10.62 % |
- |
| MEDTECH Orthopaedics HIPS |
|
6.6 % |
- |
| MEDTECH Orthopaedics HIPS U S |
|
5.32 % |
- |
| MEDTECH Orthopaedics HIPS International |
|
8.9 % |
- |
| MEDTECH Orthopaedics KNEES |
|
7.97 % |
- |
| MEDTECH Orthopaedics KNEES U S |
|
3.46 % |
- |
| MEDTECH Orthopaedics KNEES International |
|
14.56 % |
- |
| MEDTECH Orthopaedics TRAUMA |
|
7.9 % |
- |
| MEDTECH Orthopaedics TRAUMA U S |
|
5.98 % |
- |
| MEDTECH Orthopaedics TRAUMA International |
|
11.48 % |
- |
| MEDTECH Orthopaedics SPINE OTHER |
|
3.43 % |
- |
| MEDTECH Orthopaedics SPINE OTHER U S |
|
-0.26 % |
- |
| MEDTECH Orthopaedics SPINE OTHER International |
|
8.48 % |
- |
| MEDTECH Surgery |
|
4.8 % |
- |
| MEDTECH Surgery U S |
|
4.39 % |
- |
| MEDTECH Surgery International |
|
5.09 % |
- |
| MEDTECH Surgery ADVANCED |
|
4.66 % |
- |
| MEDTECH Surgery ADVANCED U S |
|
4.38 % |
- |
| MEDTECH Surgery ADVANCED International |
|
4.87 % |
- |
| MEDTECH Surgery GENERAL |
|
4.91 % |
- |
| MEDTECH Surgery GENERAL U S |
|
4.6 % |
- |
| MEDTECH Surgery GENERAL International |
|
5.27 % |
- |
| MEDTECH Vision |
|
6.72 % |
- |
| MEDTECH Vision U S |
|
2.3 % |
- |
| MEDTECH Vision International |
|
10.1 % |
- |
| MEDTECH Vision CONTACT LENSES OTHER |
|
5.44 % |
- |
| MEDTECH Vision CONTACT LENSES OTHER U S |
|
3.54 % |
- |
| MEDTECH Vision CONTACT LENSES OTHER International |
|
7.28 % |
- |
| MEDTECH Vision SURGICAL |
|
9.7 % |
- |
| MEDTECH Vision SURGICAL U S |
|
-2.63 % |
- |
| MEDTECH Vision SURGICAL International |
|
15.85 % |
- |
| United States |
|
8.33 % |
- |
| Europe |
|
14.44 % |
- |
| Western Hemisphere excluding U S |
|
10.8 % |
- |
| Asia-Pacific Africa |
|
8.46 % |
- |
| Total |
|
9.91 % |
- |
As Johnson And Johnson's income per share faded by -95.75% year on year in the third quarter, Major Pharmaceutical Preparations industry fell only by -31.6%, Johnson And Johnson's third quarter performance was trailing Major Pharmaceutical Preparations, and underperformed the -39.18% EPS slide in the Healthcare sector. Weak third quarter income per share, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Johnson And Johnson results which underperformed overall market.
Bottom-line fell by -96.04% from the second quarter results. Comparing the annual growth, income per share of 14.89% on average in last five years, to the S & P 500's, including only Businesses with the third quarter 2026 earnings, average yearly income per share growth is 23.95%. Johnson And Johnson grew less than the market.
